Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma

Histopathology

Volumn 64, Issue 6, 2014, Pages 826-839

  Allo, Ghassan ^a,b   Bandarchi, Bizhan ^a,c   Yanagawa, Naoki ^a   Wang, Ami ^a   Shih, Warren ^a   Xu, Jing ^a   Dalby, Morgan ^d   Nitta, Hiroaki ^d   To, Christine ^a   Liu, Ni ^a   Sykes, Jenna ^a   Tsao, Ming S ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Epidermal growth factor receptor; Immunohistochemistry; Lung adenocarcinoma; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR GENE; VERY ELDERLY; ADENOCARCINOMA; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84898058460     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12331     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2: cancer incidence and mortality worldwide: IARC CancerBase no. 10 [internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr. (accessed 10 April 2012).
2. Travis WD, World Health Organization, International Agency for Research on Cancer et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press, 2004.
3. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol. 2007; 25; 561-570.
4. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Ann. Rev. Pathol. 2011; 15; 49-69.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353; 123-132.
6. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin. Cancer Res. 2009; 15; 5267-5273.
7. Lara-Guerra H, Waddell TK, Salvarrey MA et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J. Clin. Oncol. 2009; 27; 6229-6236.
8. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350; 2129-2139.
9. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304; 1497-1500.
10. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. U.S.A. 2004; 101; 13306-13311.
11. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005; 353; 133-144.
12. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008; 26; 4268-4275.
13. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361; 947-957.
14. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007; 7; 169-181.
15. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin. Lung Cancer 2006; 7(Suppl. 4); S138-S144.
16. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009; 63; 315-321.
17. Cheng L, Alexander RE, Maclennan GT et al. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 2012; 25; 347-369.
18. Canadian Agency for Drugs and Technologies in Health (CADTH). Epidermal growth factor receptor mutation analysis in advanced non-small cell lung cancer: a review of the clinical effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2010. Available at: http://www.cadth.ca/media/pdf/M0017_EGFR_Testing_for_NSCLC_e.pdf (accessed 10 April 2012).
19. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 2011; 29; 2121-2127.
20. Ellis PM, Blais N, Soulieres D et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J. Thorac. Oncol. 2011; 6; 1379-1391.
21. Yu J, Kane S, Wu J et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin. Cancer Res. 2009; 15; 3023-3028.
22. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007; 39; 347-351.
23. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J. Mol. Diagn. 2005; 7; 396-403.
24. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J. Mol. Diagn. 2010; 12; 169-176.
25. Lara-Guerra H, Chung CT, Schwock J et al. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer 2012; 76; 235-241.
26. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J. Clin. Epidemiol. 1993; 46; 423-429.
27. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44; 837-845.
28. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J. Clin. Oncol. 2011; 29; 2972-2977.
29. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J. Thorac. Oncol. 2008; 3; 527-529.
30. Nakano H, Soda H, Takasu M et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008; 60; 136-140.
31. Gow CH, Chang YL, Hsu YC et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 2009; 20; 696-702.
32. Park S, Holmes-Tisch AJ, Cho EY et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 2009; 4; 809-815.
33. Tang X, Shigematsu H, Bekele BN et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005; 65; 7568-7572.
34. Ho HL, Chang FP, Ma HH et al. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese cases with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology 2013; 18; 1261-1270.
35. Cooper WA, Yu B, Yip PY et al. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J. Clin. Pathol. 2013; 66; 744-748.
36. Fan X, Liu B, Xu H et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum. Pathol. 2013; 44; 1499-1507.
37. Xiong Y, Bai Y, Leong N et al. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn. Pathol. 2013; 8; 27.
38. Kozu Y, Tsuta K, Kohno T et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011; 73; 45-50.
39. Simonetti S, Molina MA, Queralt C et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J. Transl. Med. 2010; 8; 135.
40. Kato Y, Peled N, Wynes MW et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J. Thorac. Oncol. 2010; 5; 1551-1558.
41. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin. Cancer Res. 2010; 16; 3349-3355.